Treatment options for community-acquired pneumonia in the elderly people

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Community-acquired pneumonia (CAP) represents one of the most common reasons for hospitalization in elderly people. Because older persons are the fastest growing segment of the population, a further increase of the incidence of CAP is expected in the next few years. Due to the high frequency, the different epidemiology, the atypical clinical presentation and the age-related modifications in drug metabolism that complicate the treatment, infections in the elderly people represent a major challenge for physicians. Despite the peculiarity of the management of CAP in the elderly people, no specific recommendations for antimicrobial treatment are provided in the international guidelines. The aim of this review is to give an update of the current antibiotic options for CAP in the elderly people reporting available data on the CAP etiology and risk factors, and tolerability, toxicity and pharmacokinetics/pharmacodynamic of antimicrobial agents used for elderly patients.

Original languageEnglish
Pages (from-to)473-485
Number of pages13
JournalExpert Review of Anti-Infective Therapy
Volume13
Issue number4
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Pneumonia
Therapeutics
Anti-Infective Agents
Epidemiology
Hospitalization
Research Design
Pharmacokinetics
Guidelines
Anti-Bacterial Agents
Physicians
Incidence
Infection
Pharmaceutical Preparations
Population

Keywords

  • aged persons
  • antibiotic agents
  • antibiotic-resistance
  • bacterial pneumonia
  • pharmacokinetics and pharmacodynamic characteristics

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)
  • Microbiology
  • Virology
  • Medicine(all)

Cite this

Treatment options for community-acquired pneumonia in the elderly people. / Petrosillo, Nicola; Cataldo, Maria Adriana; Pea, Federico.

In: Expert Review of Anti-Infective Therapy, Vol. 13, No. 4, 01.04.2015, p. 473-485.

Research output: Contribution to journalArticle

@article{01926510d7f0494097f90233600f6418,
title = "Treatment options for community-acquired pneumonia in the elderly people",
abstract = "Community-acquired pneumonia (CAP) represents one of the most common reasons for hospitalization in elderly people. Because older persons are the fastest growing segment of the population, a further increase of the incidence of CAP is expected in the next few years. Due to the high frequency, the different epidemiology, the atypical clinical presentation and the age-related modifications in drug metabolism that complicate the treatment, infections in the elderly people represent a major challenge for physicians. Despite the peculiarity of the management of CAP in the elderly people, no specific recommendations for antimicrobial treatment are provided in the international guidelines. The aim of this review is to give an update of the current antibiotic options for CAP in the elderly people reporting available data on the CAP etiology and risk factors, and tolerability, toxicity and pharmacokinetics/pharmacodynamic of antimicrobial agents used for elderly patients.",
keywords = "aged persons, antibiotic agents, antibiotic-resistance, bacterial pneumonia, pharmacokinetics and pharmacodynamic characteristics",
author = "Nicola Petrosillo and Cataldo, {Maria Adriana} and Federico Pea",
year = "2015",
month = "4",
day = "1",
doi = "10.1586/14787210.2015.1021783",
language = "English",
volume = "13",
pages = "473--485",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Taylor and Francis Ltd.",
number = "4",

}

TY - JOUR

T1 - Treatment options for community-acquired pneumonia in the elderly people

AU - Petrosillo, Nicola

AU - Cataldo, Maria Adriana

AU - Pea, Federico

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Community-acquired pneumonia (CAP) represents one of the most common reasons for hospitalization in elderly people. Because older persons are the fastest growing segment of the population, a further increase of the incidence of CAP is expected in the next few years. Due to the high frequency, the different epidemiology, the atypical clinical presentation and the age-related modifications in drug metabolism that complicate the treatment, infections in the elderly people represent a major challenge for physicians. Despite the peculiarity of the management of CAP in the elderly people, no specific recommendations for antimicrobial treatment are provided in the international guidelines. The aim of this review is to give an update of the current antibiotic options for CAP in the elderly people reporting available data on the CAP etiology and risk factors, and tolerability, toxicity and pharmacokinetics/pharmacodynamic of antimicrobial agents used for elderly patients.

AB - Community-acquired pneumonia (CAP) represents one of the most common reasons for hospitalization in elderly people. Because older persons are the fastest growing segment of the population, a further increase of the incidence of CAP is expected in the next few years. Due to the high frequency, the different epidemiology, the atypical clinical presentation and the age-related modifications in drug metabolism that complicate the treatment, infections in the elderly people represent a major challenge for physicians. Despite the peculiarity of the management of CAP in the elderly people, no specific recommendations for antimicrobial treatment are provided in the international guidelines. The aim of this review is to give an update of the current antibiotic options for CAP in the elderly people reporting available data on the CAP etiology and risk factors, and tolerability, toxicity and pharmacokinetics/pharmacodynamic of antimicrobial agents used for elderly patients.

KW - aged persons

KW - antibiotic agents

KW - antibiotic-resistance

KW - bacterial pneumonia

KW - pharmacokinetics and pharmacodynamic characteristics

UR - http://www.scopus.com/inward/record.url?scp=84924690284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924690284&partnerID=8YFLogxK

U2 - 10.1586/14787210.2015.1021783

DO - 10.1586/14787210.2015.1021783

M3 - Article

C2 - 25746632

AN - SCOPUS:84924690284

VL - 13

SP - 473

EP - 485

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 4

ER -